Search results for "Portal vein thrombosi"

showing 10 items of 32 documents

Identification of clinical phenotypes and related survival in patients with large hccs

2021

Background. Hepatocellular carcinoma (HCC) factors, especially maximum tumor diameter (MTD), tumor multifocality, portal vein thrombosis (PVT), and serum alpha-fetoprotein (AFP), influence survival. Aim. To examine patterns of tumor factors in large HCC patients. Methods. A database of large HCC patients was examined. Results. A multiple Cox proportional hazard model on death identified low serum albumin levels and the presence of PVT and multifocality, with each having a hazard ratio ≥2.0. All combinations of these three parameters were examined in relation to survival. Using univariate Cox analysis, the combination of albumin &gt

0301 basic medicineCancer Researchmedicine.medical_specialtyPVTSettore MED/12 - GASTROENTEROLOGIASerum albuminlcsh:RC254-282GastroenterologyArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinePlateletHCCneoplasmsSurvival ratePVT.biologybusiness.industryProportional hazards modelAlbuminHazard ratioSettore MED/09 - MEDICINA INTERNAAlbuminMultifocalityHCC; large; phenotypes; PVT; multifocality; albuminlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasedigestive system diseasesPortal vein thrombosisAlbumin; HCC; Large; Multifocality; Phenotypes; PVTPhenotypesPhenotype030104 developmental biologyOncology030220 oncology & carcinogenesisHepatocellular carcinomabiology.proteinLargebusiness
researchProduct

Systemic treatment of HCC in special populations

2020

Summary Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirr…

0301 basic medicinemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityDisease03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansMultiple Chronic ConditionsAutoimmune diseaseHepatologybusiness.industryLiver NeoplasmsConfoundingDisease ManagementImmunotherapymedicine.diseasedigestive system diseasesPortal vein thrombosis030104 developmental biologyHepatocellular carcinoma030211 gastroenterology & hepatologyMetabolic syndromebusinessJournal of Hepatology
researchProduct

PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and Prothrombin 20210A in Splanchnic Vein Thrombosis: Analysis of Individual Patient Data From Three Prospec…

2015

There are no univocal opinions on the role of genetic thrombophilia on splanchnic vein thrombosis (SVT). We defined genetic thrombophilia the presence of one of these thrombophilic genetic factors (THRGFs): PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and prothrombin 20210A.To evaluate the frequencies of these THRGFs in SVT patients, we analyzed individual data of 482 Caucasian patients, recruited from 2000 to 2014 in three prospective studies. SVT was defined as the presence of thrombosis of portal (PVT), mesenteric (MVT), splenic (SPVT), cava (CT), and hepatic vein (Budd Chiari syndrome, BCS). Pre-hepatic SVT (pre-HSVT) was defined as PVT with or without MVT/SPVT, without BCS. Post-hepatic SV…

0301 basic medicinemedicine.medical_specialtyHepatologybiologybusiness.industry030204 cardiovascular system & hematologymedicine.diseaseThrombophiliaGastroenterologyThrombosisSurgeryPortal vein thrombosis03 medical and health sciences030104 developmental biology0302 clinical medicineSplanchnic vein thrombosisInternal medicineMethylenetetrahydrofolate reductaseBudd–Chiari syndromebiology.proteinMedicineOriginal ArticlebusinessProspective cohort studyMyeloproliferative neoplasm
researchProduct

Pattern of macrovascular invasion in hepatocellular carcinoma

2021

Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed …

Ablation TechniquesMaleRegistrieCirrhosisClinical BiochemistryMesenteric Veinloco-regional treatment030204 cardiovascular system & hematologyBiochemistryGastroenterologysurgeryAntineoplastic AgentLiver disease0302 clinical medicineNon-alcoholic Fatty Liver Diseasecirrhosis; hepatocellular carcinoma; loco-regional treatment; portal vein thrombosis; surgery; transplantationAscitesAblation Techniqueportal vein thrombosisRegistries030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaPortal VeinLiver DiseasesLiver NeoplasmsAsciteshepatocellular carcinomaGeneral MedicineMiddle AgedSorafenibPrognosisHepatitis BAlcoholicHepatitis CTumor BurdenSurvival RateItalyLiver NeoplasmHepatocellular carcinomaAsciteFemalemedicine.symptomLiver cancerHumanmedicine.medical_specialtyCarcinoma HepatocellularPrognosiAntineoplastic AgentsEnd Stage Liver Disease03 medical and health sciencesMesenteric VeinsHepatitis B ChronicInternal medicinemedicineHumansHepatectomyNeoplasm Invasivenessportal vein thrombosiLiver Diseases AlcoholicAgedNeoplasm Invasivene...Performance statusbusiness.industrycirrhosisCarcinomaSettore MED/09 - MEDICINA INTERNAPatient AcuityHepatocellularHepatitis C Chronicmedicine.diseaseLiver TransplantationTransplantationLiver functionbusinesscirrhositransplantationEuropean Journal of Clinical Investigation
researchProduct

Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis

2011

Background and aims Portal vein thrombosis (PVT) negatively impacts the prognosis in patients with cirrhosis. The aim of our study was to evaluate the effects of transjugular intrahepatic portosystemic shunt (TIPS) placement in patients with cirrhosis complicated by PVT. Methods Seventy consecutive cirrhotic patients with non-tumoural PVT treated with TIPS for portal hypertension complications from January 2003 to February 2010 in a tertiary-care centre were followed until last clinical evaluation, liver transplantation, or death. Results TIPS was successfully placed without major procedure-related complications. After TIPS, the portal venous system was completely recanalised in 57% of pati…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisvenous thrombosimedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicatePortal venous systemLiver transplantationmeta-analysiSettore MED/01 - Statistica MedicaSpontaneous bacterial peritonitistransjugular intrahepatic portosystemic shuntmedicineHumansAgedVenous ThrombosisPortal Veinbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseLiver TransplantationPortal vein thrombosisSurgeryVenous thrombosisrisk-factorTreatment OutcomeLiver-transplantationPortal hypertensionFemaleRadiologyPortasystemic Shunt Transjugular IntrahepaticEpidemiologic MethodsTomography X-Ray ComputedbusinessTransjugular intrahepatic portosystemic shuntLiver Circulation
researchProduct

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis

2014

Abstract Introduction Splanchnic vein thrombosis (SVT) is a serious complication in patients with paroxysmal nocturnal hemoglobinuria (PNH). Mutant PNH clones can be associated with an increased risk of SVT even in the absence of overt disease, but their prevalence in non-selected SVT patients remains unknown. Materials and Methods Patients with objective diagnosis of SVT and without known PNH were tested for the presence of PNH clone using high-sensitivity flow cytometric analysis. Results A total of 202 SVT patients were eligible, 58.4% were males, mean age was 54.6 years (range 17–94), site of thrombosis was portal in 103 patients, mesenteric in 67, splenic in 37, and supra-hepatic in 10…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentParoxysmalHemoglobinuria ParoxysmalHemoglobinuriaGastroenterologyYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicine80 and overmedicineHumansMyeloproliferative neoplasmAgedAged 80 and overVenous Thrombosisbusiness.industryMedicine (all)Splanchnic vein thrombosisHematologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsThrombosisAdolescent; Adult; Aged; Aged 80 and over; Cross-Sectional Studies; Female; Hematopoietic Stem Cells; Hemoglobinuria Paroxysmal; Humans; Male; Middle Aged; Risk Factors; Venous Thrombosis; Young Adult; Hematology; Medicine (all)SurgeryPortal vein thrombosisVenous thrombosisSettore MED/15 - MALATTIE DEL SANGUECross-Sectional StudiesSplanchnic vein thrombosisParoxysmal nocturnal hemoglobinuriaFemaleHemoglobinuriabusiness
researchProduct

Case report: acute portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent adult

2017

Cytomegalovirus (CMV) infection is usually asymptomatic and self-limiting in healthy individuals, but significant complications can develop in immunosuppressed patients. Venous or arterial thromboembolic phenomena are uncommon yet very serious complications of CMV infection. Most published reports describe immunosuppressed patients, but thrombotic events in CMV-infected immunocompetent individuals may also occur. We describe the case of an immunocompetent young man with acute CMV hepatitis that was complicated with portal vein thrombosis (PVT). We also review the literature regarding the association between PVT and CMV in immunocompetent patients. Thromboembolism is an underestimated but si…

AdultMalemedicine.medical_specialtyPediatricsRadiology Nuclear Medicine and ImagingSettore MED/09 - Medicina InternaCmv hepatitisUsually asymptomaticCongenital cytomegalovirus infectionCase Report030204 cardiovascular system & hematologyHepatic veinPathogenesisDiagnosis Differential03 medical and health sciences0302 clinical medicineUltrasoundmedicineInternal MedicineHumansUltrasonography Doppler ColorPortal vein thrombosiVenous Thrombosisbusiness.industryPortal VeinDopplervirus diseasesCytomegaloviruGeneral Medicinemedicine.diseaseSurgeryPortal vein thrombosisCytomegalovirus infectionHealthy individualsCytomegalovirus Infections030211 gastroenterology & hepatologyImmunocompetentComplicationbusinessImmunocompetence
researchProduct

Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion.

2021

Non-cirrhotic portal vein thrombosis (PVT) in patients with antiphospholipid syndrome (APS) is a rare complication, and the management has to be determined individually based on the extent and severity of the presentation. We report on a 37-year-old male patient with non-cirrhotic chronic PVT related to a severe thrombophilia, comprising APS, antithrombin-, factor V- and factor X-deficiency. Three years after the initial diagnosis of non-cirrhotic PVT, the patient presented with severe hemorrhagic shock related to acute bleeding from esophageal varices, requiring an emergency transjugular intrahepatic portosystemic stent shunt (TIPSS). TIPSS was revised after a recurrent bleeding episode du…

AdultMalemedicine.medical_specialtyPortal venous pressuremedicine.medical_treatment030204 cardiovascular system & hematologyThrombophiliaEsophageal and Gastric Varices03 medical and health sciences0302 clinical medicineEsophageal varicesHypertension PortalmedicineHumansThrombophiliaEmbolizationPatient Care TeamVenous Thrombosisbusiness.industryPortal VeinGastroenterologymedicine.diseaseThrombosisSurgeryPortal vein thrombosisPortal hypertension030211 gastroenterology & hepatologyStentsPortasystemic Shunt Transjugular IntrahepaticbusinessVaricesGastrointestinal HemorrhageZeitschrift fur Gastroenterologie
researchProduct

"Long term anticoagulant treatment management in patients with portal vein thrombosis at high bleeding risk"

2017

anticoagulant treatment.

BleedingPortal vein thrombosis; Thrombocytopenia;BleedingPortal vein thrombosiThrombocytopenia
researchProduct

Portal vein thrombosis and Budd-Chiari syndrome as onset of Polycythaemia Vera.

2013

Budd-Chiari syndromeSettore MED/09 - Medicina InternaPolycythaemia VeraPortal vein thrombosis; Budd-Chiari syndrome; Polycythaemia VeraPortal vein thrombosi
researchProduct